Back to Search Start Over

Clinical Variability in Spinal Muscular Atrophy Type <scp>III</scp>

Authors :
Claudio Bruno
Gian Luca Vita
Jacqueline Montes
Maria Sframeli
Tina Duong
Valeria Sansone
Annalia Frongia
Mariacristina Scoto
John W. Day
Francesco Muntoni
Giorgia Coratti
Enrico Bertini
Jessica Exposito Escudero
Simona Lucibello
Marika Pane
Sonia Messina
Allan M. Glanzman
Eugenio Mercuri
Roberto De Sanctis
Elena S. Mazzone
Anna Mayhew
Laura Antonaci
Francesca Bovis
Andrés Nascimento Osorio
Matthew Civitello
Sara Carnicella
Rachel Salazar
Richard S. Finkel
Chiara Marini Bettolo
Adele D'Amico
Nathalie Goemans
Robert Muni Lofra
Darryl C. De Vivo
Marleen Van den Hauwe
Maria Carmela Pera
Evelin Milev
Amy Pasternak
Sally Dunaway Young
Emilio Albamonte
Basil T. Darras
Source :
ANNALS OF NEUROLOGY, r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu, instname, r-FSJD: Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu, Fundació Sant Joan de Déu
Publication Year :
2020
Publisher :
Wiley, 2020.

Abstract

OBJECTIVE: We report natural history data in a large cohort of 199 patients with spinal muscular atrophy (SMA) type III assessed using the Hammersmith Functional Motor Scale Expanded (HFMSE). The aim of the study was to establish the annual rate and possible patterns of progression according to a number of variables, such as age of onset, age at assessment, SMN2 copy number, and functional status. METHODS: HFMSE longitudinal changes were assessed using piecewise linear mixed-effects models. The dependency in the data due to repeated measures was accounted for by a random intercept per individual and an unstructured covariance R matrix was used as correlation structure. An additional descriptive analysis was performed for 123 patients, for a total of 375 12-month assessments. RESULTS: A break point at age 7 years was set for the whole cohort and for SMA IIIA and IIIB. Age, SMA type, and ambulatory status were significantly associated with changes in mean HFMSE score, whereas gender and SMN2 copy number were not. The increase in response before the break point of age 7 years is significant only for SMA IIIA (&#223; = 1.79, p &lt; 0.0001). After the break point, the change in the rate of HFMSE score significantly decrease for both SMA IIIA (&#223; = -1.15, p &lt; 0.0001) and IIIB (&#223; = -0.69, p = 0.002). INTERPRETATION: Our findings contribute to the understanding of the natural history of SMA type III and will be helpful in the interpretation of the real-world data of patients treated with commercially available drugs. ANN NEUROL 2020;88:1109-1117.

Details

ISSN :
15318249 and 03645134
Volume :
88
Database :
OpenAIRE
Journal :
Annals of Neurology
Accession number :
edsair.doi.dedup.....b7eff96e16ed9ca4d83cccff947b5eec